✦ LIBER ✦

Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients

✍ Scribed by Amerigo Boiardi; Antonio Silvani; Pier Adelchi Ruffini; Licia Rivoltini; Giorgio Parmiani; Giovanni Broggi; Andrea Salmaggi

Publisher: Springer-Verlag
Year: 1994
Tongue: English
Weight: 706 KB
Volume: 39
Category: Article
ISSN: 0340-7004
DOI: 10.1007/bf01533386

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adoptive immunotherapy for recurrent gli

Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2

✍ Randall E. Merchant; Angus J. Grant; Lynn H. Merchant; Harold F. Young 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 565 KB

Thirteen patients with recurrent glioblastoma were treated with adoptively transferred autologous lymphokine activated killer (LAK) cells and recombinant interleukin-2 (rIL-2). Patients' blood mononuclear cells (MNC) obtained by leukapheresis were cultured at 2.5 million MNC per ml for 3 to 5 days i

Adoptive immunotherapy with lymphokine-a

Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma

✍ Saburo Onishi; Toshiji Saibara; Masanao Fujikawa; Hiroshi Sakaeda; Yasushi Matsu 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 591 KB

Ten patients with hepatocellular carcinoma, three of whom had pulmonary metastasis, were treated with adoptive immunotherapy using autologous lymphokineactivated killer cells plus recombinant interleukin 2. Patients received 16 pg per day of recombinant interleukin 2 consecutively (for 14 to 64 days

Lack of correlation between peripheral b

Lack of correlation between peripheral blood lymphokine-activated killer (lak) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2

✍ A. K. Ghosh; H. Dazzi; N. Thatcher; M. Moore 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 634 KB

A phase-1/11 study of recombinant interleukin 2 (rll-2) was performed in 31 melanoma patients. The first dose of rlL-2 was given intrasplenically followed 4 hr later by an i.v. dose and 3 further i.v. doses on alternate days. Three courses of treatment were planned at 3-week intervals. The maximum t

Comparison of suppressor and cytotoxic a

Comparison of suppressor and cytotoxic activity of blood mononuclears during adaptive immunotherapy of cancer patients with lymphokine-activated killer cells with a low dose of recombinant interleukin-2

✍ I. F. Abronina; T. A. Kupriyanova; A. V. Bolvachova; S. N. Bykovskaya; O. M. Dro 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 345 KB

Graft-versus-host disease following inte

Graft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission: autologous LAK cells following allogeneic bone marrow transplantation are donor-derived

✍ Brian J. Boughton; Andrew W. Simpson; Trevor A. J. Phaure; Cynthia Beatty 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 638 KB

Time course of the cytotoxicity of blood

Time course of the cytotoxicity of blood mononuclears in patients with bladder cancer during endolymphatic immunotherapy with lymphokine-activated killers and recombinant interleukin-2

✍ N. V. Malakhova; K. M. Figurin; N. S. Fedorova; M. V. Kiselevskii; S. N. Bykovsk 📂 Article 📅 1996 🏛 Springer US 🌐 English ⚖ 303 KB